Tuesday, March 21, 2023
No Result
View All Result
  • Media
Support Us
Macdonald-Laurier Institute
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
    • Jobs
    • Women’s History Month Fundraiser
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy Program
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Energy Policy Program
      • Energy
      • Environment
    • Foreign Policy Program
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs Program
  • Projects
    • COVID and after: A mandate for recovery
    • COVID Misery Index
      • Beyond Lockdown
    • Provincial COVID Misery Index
    • Centre for Advancing Canada’s Interests Abroad
      • Dragon at the Door
      • The Eavesdropping Dragon: Huawei
    • An Intellectual Property Strategy for Canada
    • Competition Policy in Canada
    • Speak for Ourselves
    • Canada and the Indo-Pacific Initiative
    • DisInfoWatch.org
    • The Transatlantic Program
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Talkin’ in the Free World with Mariam Memarsadeghi
    • Past Projects
      • Justice Report Card
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Annual Reports
    • Inside Policy Magazine
      • Inside Policy Back Issues
      • Inside Policy Blog
    • Papers
    • Columns
    • Books
    • Commentary
    • Straight Talk
    • Video
    • Multimedia
    • Podcasts
    • Leading Economic Indicator
    • Labour Market Report
    • MLI in the Media
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
    • Jobs
    • Women’s History Month Fundraiser
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy Program
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Energy Policy Program
      • Energy
      • Environment
    • Foreign Policy Program
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs Program
  • Projects
    • COVID and after: A mandate for recovery
    • COVID Misery Index
      • Beyond Lockdown
    • Provincial COVID Misery Index
    • Centre for Advancing Canada’s Interests Abroad
      • Dragon at the Door
      • The Eavesdropping Dragon: Huawei
    • An Intellectual Property Strategy for Canada
    • Competition Policy in Canada
    • Speak for Ourselves
    • Canada and the Indo-Pacific Initiative
    • DisInfoWatch.org
    • The Transatlantic Program
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Talkin’ in the Free World with Mariam Memarsadeghi
    • Past Projects
      • Justice Report Card
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Annual Reports
    • Inside Policy Magazine
      • Inside Policy Back Issues
      • Inside Policy Blog
    • Papers
    • Columns
    • Books
    • Commentary
    • Straight Talk
    • Video
    • Multimedia
    • Podcasts
    • Leading Economic Indicator
    • Labour Market Report
    • MLI in the Media
No Result
View All Result
Macdonald-Laurier Institute

COVID-19 research in Canada reveals Ottawa’s unwillingness to collaborate: Nigel Rawson and John Adams for Inside Policy

February 17, 2021
in Columns, COVID-19, Domestic Policy Program, Health, Inside Policy, Latest News
Reading Time: 4 mins read
A A

Canadian governments, at all levels, must take responsibility for their inept procurement and distribution processes in their health systems, write Nigel Rawson and John Adams.

By Nigel Rawson and John Adams, February 17, 2021

The COVID-19 pandemic has cost lives and caused much fear in Canada. Outside Canada, biopharmaceutical industry, academic and government scientists working together have developed effective vaccines to protect against the virus in record time. But Canada lags most other industrialized countries in producing and receiving vaccines. Why?

Could it be that Canada only constitutes 2 percent of the world market for pharmaceuticals? Is it related to the lack of collaboration that biopharmaceutical companies have received from Canadian federal governments over several decades?

One indicator of the enthusiasm of developers in launching a medicine is their investment in pursuing clinical trials in a country. This is especially relevant for pivotal, late-stage, large-scale trials. Not only are these expensive but they bring an ethical obligation under the Declaration of Helsinki to “make provisions for post-trial access for all participants who still need an intervention identified as beneficial in the trial.”

What about clinical trials of COVID-19 therapies and vaccines?

The ClinicalTrials.gov database of studies conducted worldwide, which is maintained by the US National Library of Medicine, lists 625 interventional trials of therapies intended to treat COVID-19 or vaccines designed to protect against the virus posted in the year between February 1, 2020 and January 31, 2021.

Biopharmaceutical developers provide all or some funding for all 625 trials. For 392 trials (63 percent), a company is the sole funder and, for a further 117 (19 percent), a company is the lead funder supported by another organization – thus, the primary funder of 81 percent of the trials is a manufacturer. Only 116 trials (19 percent) have a non-industry principal funder.

Two-thirds of the trials are ongoing and 21 percent are apparently active but “not yet recruiting.” Only 48 (eight percent) have been completed, while 35 (six percent) have been withdrawn, suspended or are no longer available.

The majority of the trials (86 percent) are testing treatments for COVID-19. Most of these treatments are therapies for other diseases which are being tested to see if they can be re-purposed to treat COVID-19. They include remdesivir and hydroxychloroquine.

Ninety of the trials are testing vaccines. Some are evaluating existing vaccines, but most are testing newly developed products, including candidates from Pfizer/BioNTech, Moderna, AstraZeneca, Johnson and Johnson, Novavax, the Russian Gamaleya National Centre (Sputnik V), and Curevac. The 90 trials have test sites in 40 countries on six continents. The countries with the largest numbers of trials are the United States (24), China (11), Japan (8), Germany (8) and Belgium (7). All the other countries have five or fewer trials.

What about Canada?

Twenty-six of the 625 trials (four percent) involve Canada, of which 19 are industry-led. Only 10 trials, less than 2 percent, are being performed by Canadian-based companies. The other nine are being carried out by companies based outside Canada – the only relation with this country is that they include a Canadian test site.

The seven remaining trials have an academic or health care institution (six Canadian and one American) as the lead funder. All seven are at least partly funded by a biopharmaceutical company.

Only five of the industry-led Canadian trials are testing a vaccine, all but one of which are early phase studies. Two trials are evaluating the vaccine developed by Medicago, a subsidiary of a Japanese company, one is assessing an oral vaccine developed by Immunitor, a Thailand-based company, and another is testing a vaccine developed by Entos Pharmaceuticals in Edmonton. The final vaccine trial is the CanSino trial cancelled after the Chinese company or government withheld critical virus samples.

What can we conclude from these numbers?

First, the COVID trials data reconfirm that Canada does not have a major role in vaccine development. Our country does not even merit a walk-on extra role.

Second, we are seeing the results of federal and provincial governments’ adversarial approach to dealing with the biopharmaceutical industry. For decades, governments have raised barriers against innovative medicines and vaccines such as bureaucratic and unreceptive health technology assessment processes and aggressive price negotiations, which do not deliver guaranteed coverage by government drug plans.

In July, Ottawa intends to add another obstacle when it changes the regulations of the Patented Medicine Prices Review Board (PMPRB) – the federal agency whose role is to ensure the prices for patented medicines are not excessive – that will further disincentivize drug and vaccine developers from launching new products in Canada. The objective of the changes is radical price reduction of new innovative technologies, even if it means Canadians’ access to them is delayed for years or denied altogether. Ottawa is aware of the negative consequences the new rules will bring because it exempted COVID-19 vaccines and medicines from the PMPRB’s regular scrutiny.

Canadians should not be surprised that their country is not a priority for vaccine makers, but they should be concerned about Ottawa’s mismanagement of the vaccine procurement process. It is just one symptom of the long-standing negativity towards the biopharmaceutical industry. Canadian governments, at all levels, must take responsibility for their inept procurement and distribution processes in their health systems and recognize that the biopharmaceutical industry can bring both health and economic benefits to Canada if governments were collaborative.

Nigel Rawson is an independent researcher and affiliate scholar with the Canadian Health Policy Institute. John Adams, co-founder and CEO of Canadian PKU and Allied Disorders Inc., is volunteer board chair of the Best Medicines Coalition.

Tags: COVID-19DrugsHealthhealthcareJohn AdamsMedicineNigel Rawsonpharmaceuticalsvaccines
Previous Post

Canadian Coalition: Can it make a difference? Sarah Teich on CBC News

Next Post

Canada should say no to racism at the United Nations: Sarah Teich and David Matas in iPolitics

Related Posts

Oaths, trust and Canadian democracy: Stephen Van Dine and Karl Salgo for Inside Policy
Inside Policy

Oaths, trust and Canadian democracy: Stephen Van Dine and Karl Salgo for Inside Policy

March 17, 2023
Preparing for the Foreign Threats to Canadian Democracy: Straight Talk with Richard Fadden
Inside Policy

Canada and Japan’s common miscalculation in cyberspace: Koichiro Komiyama for Inside Policy

March 15, 2023
Defending against foreign interference in our elections: Marcus Kolga for Inside Policy
Columns

As Ottawa balks at an election interference inquiry, public trust in our democracy is draining away: Marcus Kolga in the Globe and Mail

March 15, 2023
Next Post
The UN keeps snubbing Canada’s international policy. When will we hear its message?: Bruno Charbonneau and Christian Leuprecht in the Globe and Mail

Canada should say no to racism at the United Nations: Sarah Teich and David Matas in iPolitics

Macdonald-Laurier Institute

323 Chapel Street, Suite #300
Ottawa, Ontario
K1N 7Z2 Canada

613.482.8327

info@macdonaldlaurier.ca
MLI directory

Follow us on

Newsletter Signup

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

Inside Policy Magazine

  • Current Issue
  • Back Issues
  • Advertising
  • Inside Policy Blog
  • Privacy Policy

© 2021 Macdonald-Laurier Institute. All Rights reserved.

No Result
View All Result
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
    • Jobs
    • Women’s History Month Fundraiser
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy Program
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Energy Policy Program
      • Energy
      • Environment
    • Foreign Policy Program
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs Program
  • Projects
    • COVID and after: A mandate for recovery
    • COVID Misery Index
      • Beyond Lockdown
    • Provincial COVID Misery Index
    • Centre for Advancing Canada’s Interests Abroad
      • Dragon at the Door
      • The Eavesdropping Dragon: Huawei
    • An Intellectual Property Strategy for Canada
    • Competition Policy in Canada
    • Speak for Ourselves
    • Canada and the Indo-Pacific Initiative
    • DisInfoWatch.org
    • The Transatlantic Program
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Talkin’ in the Free World with Mariam Memarsadeghi
    • Past Projects
      • Justice Report Card
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Annual Reports
    • Inside Policy Magazine
      • Inside Policy Back Issues
      • Inside Policy Blog
    • Papers
    • Columns
    • Books
    • Commentary
    • Straight Talk
    • Video
    • Multimedia
    • Podcasts
    • Leading Economic Indicator
    • Labour Market Report
    • MLI in the Media

© 2021 Macdonald-Laurier Institute. All Rights reserved.